Cost-Efficient Biosimilar MAbs Drive The Monoclonal Antibodies Market

Monoclonal Antibodies (MAbs) Market Report 2021 - COVID-19 Impact And Recovery

Monoclonal Antibodies (MAbs) Global Market Report 2021 – COVID-19 Impact And Recovery

The Business Research Company’s Monoclonal Antibodies (MAbs) Global Market Report 2021 – COVID-19 Impact And Recovery

LONDON, GREATER LONDON, UK, October 1, 2021 / — Increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibodies (MAbs) market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar are comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

The global monoclonal antibodies (MAbs) market size is expected to grow from $106.87 billion in 2020 to $114.43 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs market is expected to reach $179.56 billion in 2025 at a CAGR of 11.9%.

Read More On The Global Monoclonal Antibodies (MAbs) Market Report:

Major players covered in the global monoclonal antibodies industry are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc.
TBRC’s global Monoclonal Antibodies (MAbs) Market report is segmented by source into murine, chimeric, humanized, human, by application into anti-cancer, immunological, anti-infective monoclonal antibodies, neuropharmacological, cardiovascular and cerebrovascular, others, and by end users into hospitals, private clinics, research institute.

Monoclonal Antibodies (MAbs) Global Market Report 2021 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End Users (Hospitals, Private Clinics, Research Institute), COVID-19 Impact And Recovery is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MAbs) market overview, forecast monoclonal antibodies (MAbs) market size and growth for the whole market, monoclonal antibodies (MAbs) market segments, and geographies, monoclonal antibodies (MAbs) market trends, monoclonal antibodies (MAbs) market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Monoclonal Antibodies (MAbs) Market Report:

Here Is A List Of Similar Reports By The Business Research Company:

Biosimilar Monoclonal Antibodies Global Market Report 2021 – By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), COVID-19 Growth And Change

Biologics Global Market Report 2021 – By Type (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), COVID-19 Impact and Recovery

Immunosuppressants Global Market Report 2021 – By Drug Class (Corticosteroids, Monoclonal Antibodies (MAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), COVID-19 Growth And Change

Interested to know more about The Business Research Company?

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at

Or get a quick glimpse of our services here:

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Follow us on LinkedIn:
Follow us on Twitter:
Check out our Blog:

Oliver Guirdham
The Business Research Company
20 7193 0708
Visit us on social media:

Leave a Reply

Your email address will not be published.